Australian cash for new drugs comes with strings
This article was originally published in Scrip
The Australian government is to provide an extra Aus$1.3bn (US$1.04bn) over five years to fund the listing of new medicines and vaccines on the Pharmaceutical Benefits Scheme (PBS), as part of a drive to improve patient access to innovative life-saving therapies.
You may also be interested in...
The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.
Health ministers have called for more action on access to medicines, including a new EU work agenda, rebuilding Europe’s manufacturing capabilities, further action on pricing, and greater leeway for member states to mitigate drug shortages by restricting parallel exports.
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.